Research
Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) and dual agonists produce significant weight loss (15-22.5%) but are associated with lean muscle mass loss and require long-term adherence.
GLP-1 drugs like semaglutide and tirzepatide are highly effective for weight loss (15-22%), but you must take them long-term to maintain results. They can cause muscle loss, so combine them with resistance training and high protein intake. Be aware of GI side effects and contraindications like thyroid cancer history.
GoodQualifiesHIGH confidence
Tirzepatide is a dual GIP/GLP-1 RA that demonstrates greater efficacy, with 22.5% total body weight loss reported in the SURMOUNT-1 trial ... recent data, however, suggest that the fat mass reduction achieved by tirzepatide and other incretin-based therapies may be accompanied by a loss of lean muscle mass as well.
Why this rating
Cites specific RCTs (SURMOUNT-1, STEP 8) and meta-analyses.
Source
Medical vs. Surgical Obesity Management: A Narrative Review of Efficacy, Safety, and Long-Term Outcomes
Joyce Akwe et al. · Cureus · 2025
DOI 10.7759/cureus.91677
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery provides superior, durable weight loss and metabolic improvement compared to non-surgical interventions, including pharmacotherapy.Good
- Lifestyle modifications (diet, exercise, behavioral therapy) are foundational but have limited efficacy for severe obesity when used alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →